Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424927 · ClinicalTrials.gov registry record · Phase 2
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
A Phase 2 study, sponsored by Provention Bio, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 388
- Enrollment target
NCT04424927 is a Phase 2 study that has completed, run by Provention Bio, a Sanofi Company. The registered enrollment target is 388 participants.
The verdict
NCT04424927, a Phase 2 study, has completed, sponsored by Provention Bio, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 388 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).
Interventions
- OTHER Placebo
- BIOLOGICAL PRV-015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424927
The ClinicalTrials.gov registry entry for NCT04424927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Provention Bio, a Sanofi Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04424927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04424927 about?
NCT04424927 is a clinical study titled "PRV-015 in Gluten-free Diet Non-responsive Celiac Disease". This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).
What is the current status of trial NCT04424927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 388 participants. The study started on 2020-08-24. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT04424927?
The interventions under investigation include: Placebo (OTHER), PRV-015 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04424927?
This trial is sponsored by Provention Bio, a Sanofi Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.